Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Berenberg to hold a virtual conference » 09:35
05/11/21
05/11
09:35
05/11/21
09:35
QGEN

Qiagen

$46.90 /

-0.75 (-1.57%)

, TCHBF

Tecan

$479.67 /

+ (+0.00%)

, SMMNY

Siemens Healthineers

$28.65 /

-1.025 (-3.45%)

, RHHBY

Roche

$41.58 /

-0.55 (-1.31%)

Diagnostics Virtual…

Diagnostics Virtual Conference 2021 to be held on May 11.

ShowHide Related Items >><<
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
TCHBF Tecan
$479.67 /

+ (+0.00%)

03/31/21 Berenberg
Tecan upgraded to Buy from Hold at Berenberg
03/23/21 UBS
Tecan price target lowered to CHF 440 from CHF 455 at UBS
02/19/21 Berenberg
Tecan price target raised to CHF 430 from CHF 415 at Berenberg
08/27/20 Berenberg
Berenberg sees Tecan at 'toppy levels,' downgrades to Hold
SMMNY Siemens Healthineers
$28.65 /

-1.025 (-3.45%)

05/04/21 JPMorgan
Siemens Healthineers price target lowered to EUR 54.40 at JPMorgan
05/04/21 Credit Suisse
Siemens Healthineers price target raised to EUR 55 from EUR 54 at Credit Suisse
05/04/21 Deutsche Bank
Siemens Healthineers upgraded to Buy from Hold at Deutsche Bank
04/30/21 Barclays
Siemens Healthineers price target raised to EUR 47 from EUR 41 at Barclays
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
SMMNY Siemens Healthineers
$28.65 /

-1.025 (-3.45%)

RHHBY Roche
$41.58 /

-0.55 (-1.31%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

SMMNY Siemens Healthineers
$28.65 /

-1.025 (-3.45%)

RHHBY Roche
$41.58 /

-0.55 (-1.31%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

RHHBY Roche
$41.58 /

-0.55 (-1.31%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

Monday
Hot Stocks
Prothena achieves $60M milestone from Roche collaboration » 16:12
05/10/21
05/10
16:12
05/10/21
16:12
PRTA

Prothena

$23.52 /

-0.905 (-3.71%)

, RHHBY

Roche

$41.58 /

-0.55 (-1.31%)

Prothena Corporation…

Prothena Corporation announced that the company has earned a $60M milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease. Prothena has previously received $75M in payments from Roche as part of this collaboration.

ShowHide Related Items >><<
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

PRTA Prothena
$23.52 /

-0.905 (-3.71%)

PRTA Prothena
$23.52 /

-0.905 (-3.71%)

03/15/21 Jefferies
Prothena price target raised to $38 from $30 at Jefferies
02/26/21 RBC Capital
Prothena upgraded to Outperform from Sector Perform at RBC Capital
02/26/21 RBC Capital
Prothena upgraded to Outperform from Sector Perform at RBC Capital
02/12/21 Jefferies
Jefferies upgrades 'very cheap' Prothena to Buy, doubles target to $30
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

PRTA Prothena
$23.52 /

-0.905 (-3.71%)

  • 24
    Mar
RHHBY Roche
$41.58 /

-0.55 (-1.31%)

RHHBY Roche
$41.58 /

-0.55 (-1.31%)

PRTA Prothena
$23.52 /

-0.905 (-3.71%)

Saturday
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
05/08/21
05/08
04:55
05/08/21
04:55
PFE

Pfizer

$39.57 /

+0.38 (+0.97%)

, NVS

Novartis

$87.97 /

+0.62 (+0.71%)

, LLY

Eli Lilly

$195.47 /

+1.64 (+0.85%)

, GILD

Gilead

$66.54 /

+ (+0.00%)

, SNY

Sanofi

$51.85 /

+0.85 (+1.67%)

, RHHBY

Roche

$42.13 /

+0.86 (+2.08%)

, EXAS

Exact Sciences

$104.48 /

-3.47 (-3.21%)

, NTRA

Natera

$101.79 /

+5.47 (+5.68%)

, SGEN

Seagen

$139.74 /

+3.73 (+2.74%)

ESMO Breast Cancer…

ESMO Breast Cancer Virtual Congress 2021 will be held on May 5-8. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$51.85 /

+0.85 (+1.67%)

SGEN Seagen
$139.74 /

+3.73 (+2.74%)

RHHBY Roche
$42.13 /

+0.86 (+2.08%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

NVS Novartis
$87.97 /

+0.62 (+0.71%)

NTRA Natera
$101.79 /

+5.47 (+5.68%)

LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

GILD Gilead
$66.54 /

+ (+0.00%)

EXAS Exact Sciences
$104.48 /

-3.47 (-3.21%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
NVS Novartis
$87.97 /

+0.62 (+0.71%)

04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
GILD Gilead
$66.54 /

+ (+0.00%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
SNY Sanofi
$51.85 /

+0.85 (+1.67%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
RHHBY Roche
$42.13 /

+0.86 (+2.08%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
EXAS Exact Sciences
$104.48 /

-3.47 (-3.21%)

05/05/21 Craig-Hallum
Exact Sciences price target lowered to $144 from $161 at Craig-Hallum
05/05/21 BTIG
Exact Sciences price target lowered to $155 from $175 at BTIG
02/18/21 Baird
Exact Sciences price target lowered to $163 from $169 at Baird
02/17/21 Stifel
Exact Sciences price target raised to $165 from $150 at Stifel
NTRA Natera
$101.79 /

+5.47 (+5.68%)

04/22/21 SVB Leerink
CMS coverage determination a positive for Natera, says SVB Leerink
03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
SGEN Seagen
$139.74 /

+3.73 (+2.74%)

04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SNY Sanofi
$51.85 /

+0.85 (+1.67%)

SGEN Seagen
$139.74 /

+3.73 (+2.74%)

RHHBY Roche
$42.13 /

+0.86 (+2.08%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

NVS Novartis
$87.97 /

+0.62 (+0.71%)

NTRA Natera
$101.79 /

+5.47 (+5.68%)

LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

GILD Gilead
$66.54 /

+ (+0.00%)

EXAS Exact Sciences
$104.48 /

-3.47 (-3.21%)

  • 11
    Sep
SNY Sanofi
$51.85 /

+0.85 (+1.67%)

RHHBY Roche
$42.13 /

+0.86 (+2.08%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

NVS Novartis
$87.97 /

+0.62 (+0.71%)

LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

GILD Gilead
$66.54 /

+ (+0.00%)

SNY Sanofi
$51.85 /

+0.85 (+1.67%)

SGEN Seagen
$139.74 /

+3.73 (+2.74%)

RHHBY Roche
$42.13 /

+0.86 (+2.08%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

NVS Novartis
$87.97 /

+0.62 (+0.71%)

NTRA Natera
$101.79 /

+5.47 (+5.68%)

LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

GILD Gilead
$66.54 /

+ (+0.00%)

EXAS Exact Sciences
$104.48 /

-3.47 (-3.21%)

PFE Pfizer
$39.57 /

+0.38 (+0.97%)

LLY Eli Lilly
$195.47 /

+1.64 (+0.85%)

GILD Gilead
$66.54 /

+ (+0.00%)

Friday
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
05/07/21
05/07
04:55
05/07/21
04:55
PFE

Pfizer

$39.19 /

-0.39 (-0.99%)

, NVS

Novartis

$87.36 /

+0.81 (+0.94%)

, LLY

Eli Lilly

$193.83 /

+0.98 (+0.51%)

, GILD

Gilead

$66.54 /

+0.02 (+0.03%)

, SNY

Sanofi

$51.00 /

+0.41 (+0.81%)

, RHHBY

Roche

$41.27 /

+0.4 (+0.98%)

, EXAS

Exact Sciences

$107.95 /

-2.62 (-2.37%)

, NTRA

Natera

$96.39 /

-8.295 (-7.92%)

, SGEN

Seagen

$136.06 /

+0.87 (+0.64%)

ESMO Breast Cancer…

ESMO Breast Cancer Virtual Congress 2021 will be held on May 5-8. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$51.00 /

+0.41 (+0.81%)

SGEN Seagen
$136.06 /

+0.87 (+0.64%)

RHHBY Roche
$41.27 /

+0.4 (+0.98%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

NVS Novartis
$87.36 /

+0.81 (+0.94%)

NTRA Natera
$96.39 /

-8.295 (-7.92%)

LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

GILD Gilead
$66.54 /

+0.02 (+0.03%)

EXAS Exact Sciences
$107.95 /

-2.62 (-2.37%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
NVS Novartis
$87.36 /

+0.81 (+0.94%)

04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
GILD Gilead
$66.54 /

+0.02 (+0.03%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
SNY Sanofi
$51.00 /

+0.41 (+0.81%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
RHHBY Roche
$41.27 /

+0.4 (+0.98%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
EXAS Exact Sciences
$107.95 /

-2.62 (-2.37%)

05/05/21 Craig-Hallum
Exact Sciences price target lowered to $144 from $161 at Craig-Hallum
05/05/21 BTIG
Exact Sciences price target lowered to $155 from $175 at BTIG
02/18/21 Baird
Exact Sciences price target lowered to $163 from $169 at Baird
02/17/21 Stifel
Exact Sciences price target raised to $165 from $150 at Stifel
NTRA Natera
$96.39 /

-8.295 (-7.92%)

04/22/21 SVB Leerink
CMS coverage determination a positive for Natera, says SVB Leerink
03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
SGEN Seagen
$136.06 /

+0.87 (+0.64%)

04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SNY Sanofi
$51.00 /

+0.41 (+0.81%)

SGEN Seagen
$136.06 /

+0.87 (+0.64%)

RHHBY Roche
$41.27 /

+0.4 (+0.98%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

NVS Novartis
$87.36 /

+0.81 (+0.94%)

NTRA Natera
$96.39 /

-8.295 (-7.92%)

LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

GILD Gilead
$66.54 /

+0.02 (+0.03%)

EXAS Exact Sciences
$107.95 /

-2.62 (-2.37%)

  • 11
    Sep
SNY Sanofi
$51.00 /

+0.41 (+0.81%)

RHHBY Roche
$41.27 /

+0.4 (+0.98%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

NVS Novartis
$87.36 /

+0.81 (+0.94%)

LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

GILD Gilead
$66.54 /

+0.02 (+0.03%)

SNY Sanofi
$51.00 /

+0.41 (+0.81%)

SGEN Seagen
$136.06 /

+0.87 (+0.64%)

RHHBY Roche
$41.27 /

+0.4 (+0.98%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

NVS Novartis
$87.36 /

+0.81 (+0.94%)

NTRA Natera
$96.39 /

-8.295 (-7.92%)

LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

GILD Gilead
$66.54 /

+0.02 (+0.03%)

EXAS Exact Sciences
$107.95 /

-2.62 (-2.37%)

PFE Pfizer
$39.19 /

-0.39 (-0.99%)

LLY Eli Lilly
$193.83 /

+0.98 (+0.51%)

GILD Gilead
$66.54 /

+0.02 (+0.03%)

Over a week ago
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
05/06/21
05/06
04:55
05/06/21
04:55
PFE

Pfizer

$39.58 /

-0.39 (-0.98%)

, NVS

Novartis

$86.51 /

+0.87 (+1.02%)

, LLY

Eli Lilly

$192.85 /

+4.62 (+2.45%)

, GILD

Gilead

$66.52 /

+0.87 (+1.33%)

, SNY

Sanofi

$50.56 /

+0.12 (+0.24%)

, RHHBY

Roche

$40.87 /

+0.14 (+0.34%)

, EXAS

Exact Sciences

$110.59 /

-5.29 (-4.57%)

, NTRA

Natera

$104.96 /

-1.99 (-1.86%)

, SGEN

Seagen

$135.19 /

-0.96 (-0.71%)

ESMO Breast Cancer…

ESMO Breast Cancer Virtual Congress 2021 will be held on May 5-8. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$50.56 /

+0.12 (+0.24%)

SGEN Seagen
$135.19 /

-0.96 (-0.71%)

RHHBY Roche
$40.87 /

+0.14 (+0.34%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

NVS Novartis
$86.51 /

+0.87 (+1.02%)

NTRA Natera
$104.96 /

-1.99 (-1.86%)

LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

GILD Gilead
$66.52 /

+0.87 (+1.33%)

EXAS Exact Sciences
$110.59 /

-5.29 (-4.57%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
NVS Novartis
$86.51 /

+0.87 (+1.02%)

04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
GILD Gilead
$66.52 /

+0.87 (+1.33%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
SNY Sanofi
$50.56 /

+0.12 (+0.24%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
RHHBY Roche
$40.87 /

+0.14 (+0.34%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
EXAS Exact Sciences
$110.59 /

-5.29 (-4.57%)

05/05/21 Craig-Hallum
Exact Sciences price target lowered to $144 from $161 at Craig-Hallum
05/05/21 BTIG
Exact Sciences price target lowered to $155 from $175 at BTIG
02/18/21 Baird
Exact Sciences price target lowered to $163 from $169 at Baird
02/17/21 Stifel
Exact Sciences price target raised to $165 from $150 at Stifel
NTRA Natera
$104.96 /

-1.99 (-1.86%)

04/22/21 SVB Leerink
CMS coverage determination a positive for Natera, says SVB Leerink
03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
SGEN Seagen
$135.19 /

-0.96 (-0.71%)

04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SNY Sanofi
$50.56 /

+0.12 (+0.24%)

SGEN Seagen
$135.19 /

-0.96 (-0.71%)

RHHBY Roche
$40.87 /

+0.14 (+0.34%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

NVS Novartis
$86.51 /

+0.87 (+1.02%)

NTRA Natera
$104.96 /

-1.99 (-1.86%)

LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

GILD Gilead
$66.52 /

+0.87 (+1.33%)

EXAS Exact Sciences
$110.59 /

-5.29 (-4.57%)

  • 11
    Sep
SNY Sanofi
$50.56 /

+0.12 (+0.24%)

RHHBY Roche
$40.87 /

+0.14 (+0.34%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

NVS Novartis
$86.51 /

+0.87 (+1.02%)

LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

GILD Gilead
$66.52 /

+0.87 (+1.33%)

SNY Sanofi
$50.56 /

+0.12 (+0.24%)

SGEN Seagen
$135.19 /

-0.96 (-0.71%)

RHHBY Roche
$40.87 /

+0.14 (+0.34%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

NVS Novartis
$86.51 /

+0.87 (+1.02%)

NTRA Natera
$104.96 /

-1.99 (-1.86%)

LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

GILD Gilead
$66.52 /

+0.87 (+1.33%)

EXAS Exact Sciences
$110.59 /

-5.29 (-4.57%)

PFE Pfizer
$39.58 /

-0.39 (-0.98%)

LLY Eli Lilly
$192.85 /

+4.62 (+2.45%)

GILD Gilead
$66.52 /

+0.87 (+1.33%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 10:36
05/05/21
05/05
10:36
05/05/21
10:36
PFE

Pfizer

$40.74 /

+0.765 (+1.91%)

, NVS

Novartis

$86.15 /

+0.51 (+0.60%)

, LLY

Eli Lilly

$191.49 /

+3.26 (+1.73%)

, GILD

Gilead

$66.32 /

+0.67 (+1.02%)

, SNY

Sanofi

$50.50 /

+0.06 (+0.12%)

, RHHBY

Roche

$40.73 /

-0.62 (-1.50%)

, EXAS

Exact Sciences

$114.64 /

-1.24 (-1.07%)

, NTRA

Natera

$105.90 /

-1.05 (-0.98%)

, SGEN

Seagen

$136.86 /

+0.71 (+0.52%)

ESMO Breast Cancer…

ESMO Breast Cancer Virtual Congress 2021 will be held on May 5-8. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$50.50 /

+0.06 (+0.12%)

SGEN Seagen
$136.86 /

+0.71 (+0.52%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

NVS Novartis
$86.15 /

+0.51 (+0.60%)

NTRA Natera
$105.90 /

-1.05 (-0.98%)

LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

GILD Gilead
$66.32 /

+0.67 (+1.02%)

EXAS Exact Sciences
$114.64 /

-1.24 (-1.07%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
NVS Novartis
$86.15 /

+0.51 (+0.60%)

04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
GILD Gilead
$66.32 /

+0.67 (+1.02%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
SNY Sanofi
$50.50 /

+0.06 (+0.12%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
EXAS Exact Sciences
$114.64 /

-1.24 (-1.07%)

05/05/21 Craig-Hallum
Exact Sciences price target lowered to $144 from $161 at Craig-Hallum
05/05/21 BTIG
Exact Sciences price target lowered to $155 from $175 at BTIG
02/18/21 Baird
Exact Sciences price target lowered to $163 from $169 at Baird
02/17/21 Stifel
Exact Sciences price target raised to $165 from $150 at Stifel
NTRA Natera
$105.90 /

-1.05 (-0.98%)

04/22/21 SVB Leerink
CMS coverage determination a positive for Natera, says SVB Leerink
03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
SGEN Seagen
$136.86 /

+0.71 (+0.52%)

04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SNY Sanofi
$50.50 /

+0.06 (+0.12%)

SGEN Seagen
$136.86 /

+0.71 (+0.52%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

NVS Novartis
$86.15 /

+0.51 (+0.60%)

NTRA Natera
$105.90 /

-1.05 (-0.98%)

LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

GILD Gilead
$66.32 /

+0.67 (+1.02%)

EXAS Exact Sciences
$114.64 /

-1.24 (-1.07%)

  • 11
    Sep
SNY Sanofi
$50.50 /

+0.06 (+0.12%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

NVS Novartis
$86.15 /

+0.51 (+0.60%)

LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

GILD Gilead
$66.32 /

+0.67 (+1.02%)

SNY Sanofi
$50.50 /

+0.06 (+0.12%)

SGEN Seagen
$136.86 /

+0.71 (+0.52%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

NVS Novartis
$86.15 /

+0.51 (+0.60%)

NTRA Natera
$105.90 /

-1.05 (-0.98%)

LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

GILD Gilead
$66.32 /

+0.67 (+1.02%)

EXAS Exact Sciences
$114.64 /

-1.24 (-1.07%)

PFE Pfizer
$40.74 /

+0.765 (+1.91%)

LLY Eli Lilly
$191.49 /

+3.26 (+1.73%)

GILD Gilead
$66.32 /

+0.67 (+1.02%)

Initiation
Mereo BioPharma initiated with a Buy at BTIG » 07:18
05/05/21
05/05
07:18
05/05/21
07:18
MREO

Mereo BioPharma

$3.52 /

+0.015 (+0.43%)

, MRK

Merck

$76.00 /

+0.03 (+0.04%)

, RHHBY

Roche

$40.73 /

-0.62 (-1.50%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Mereo BioPharma (MREO) with a Buy rating and $10 price target. The stock appears to be "significantly undervalued" given the "abundant" proof-of-concept data that is de-risking its "diversified" pipeline, the analyst tells investors in a research note. Roche (RHHBY) and Merck's (MRK) positive data provide strong validation for Mereo's anti-TIGIT monoclonal antibody given the structural similarity, Zhong adds.

ShowHide Related Items >><<
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

04/05/21 Needham
Mereo BioPharma initiated with a Buy at Needham
MRK Merck
$76.00 /

+0.03 (+0.04%)

04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

  • 10
    Feb
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

Hot Stocks
Roche's Tecentriq approved by EC as first-line monotherapy for metastatic NSCLC » 07:12
05/05/21
05/05
07:12
05/05/21
07:12
RHHBY

Roche

$40.73 /

-0.62 (-1.50%)

Roche announced that the…

Roche announced that the European Commission has approved Tecentriq as a first-line treatment for adults with metastatic non-small cell lung cancer, or NSCLC, whose tumors have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. "Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options, allowing administration every two, three or four weeks, giving physicians and patients greater flexibility on how they manage their treatment," Roche said.

ShowHide Related Items >><<
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

Hot Stocks
Atea Pharmaceuticals announces first patient dosed in MORNINGSKY trial » 05:43
04/29/21
04/29
05:43
04/29/21
05:43
AVIR

Atea Pharmaceuticals

$26.57 /

-7.025 (-20.91%)

, RHHBY

Roche

$41.50 /

-0.35 (-0.84%)

Atea Pharmaceuticals…

Atea Pharmaceuticals (AVIR) announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial, which is anticipated to enroll approximately 1,400 non-hospitalized adults and adolescents with mild to moderate COVID-19, is currently enrolling patients at clinical trial sites outside the United States. MORNINGSKY is expected to have an extensive global footprint and will include a large number of clinical sites worldwide, including Japan. AT-527 is an orally administered, direct-acting antiviral in development and derived from Atea's purine nucleotide prodrug platform. Under a strategic collaboration, Roche (RHHBY) and Atea are jointly developing AT-527 for the treatment of COVID-19.

ShowHide Related Items >><<
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

AVIR Atea Pharmaceuticals
$26.57 /

-7.025 (-20.91%)

AVIR Atea Pharmaceuticals
$26.57 /

-7.025 (-20.91%)

04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

  • 30
    Oct
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

RHHBY Roche
$41.50 /

-0.35 (-0.84%)

AVIR Atea Pharmaceuticals
$26.57 /

-7.025 (-20.91%)

AVIR Atea Pharmaceuticals
$26.57 /

-7.025 (-20.91%)

Hot Stocks
FDA panel votes for maintaining accelerated approval of Genentech's Tecentriq » 16:22
04/28/21
04/28
16:22
04/28/21
16:22
RHHBY

Roche

$41.50 /

-0.35 (-0.84%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq(R) (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1-stained tumor-infiltrating immune cells covering greater than or equal to5 percent of the tumor area) as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Today's ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts though the recommendations are not binding. The FDA has not announced when it will make its final decision for Tecentriq in this indication.

ShowHide Related Items >><<
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

RHHBY Roche
$41.50 /

-0.35 (-0.84%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$41.50 /

-0.35 (-0.84%)

RHHBY Roche
$41.50 /

-0.35 (-0.84%)

RHHBY Roche
$41.50 /

-0.35 (-0.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.